Shopping Cart
- Remove All
Your shopping cart is currently empty
Orilanolimab
😃Good
Catalog No. T78325Cas No. 2066544-85-0
Alias SYNT001
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses and related innate and adaptive immunity pathways [1] [2].
Orilanolimab
Orilanolimab
😃Good
Catalog No. T78325Alias SYNT001Cas No. 2066544-85-0
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses and related innate and adaptive immunity pathways [1] [2].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Backorder | |
| 5 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses and related innate and adaptive immunity pathways [1] [2]. |
| In vitro | Orilanolimab at concentrations of 10nM, 50nM, and 100nM administered over 48 hours, inhibits the production of CD11c+ IFN-γ in B2M TG/TG FCGRT TG/TG Fcgrt -/- mice [1]. |
| In vivo | Orilanolimab (20mg/kg; intravenous injection) significantly reduced plasma concentrations of HuLys11 in a murine model [1]. Dose-dependent and specific reductions in the circulating levels of IgG in cynomolgus monkeys were observed following orilanolimab administration (10-100 mg/kg; intravenous injection; every 5 weeks) [1]. |
| Alias | SYNT001 |
| Cas No. | 2066544-85-0 |
Storage & Solubility Information
| Storage | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Orilanolimab | purchase Orilanolimab | Orilanolimab cost | order Orilanolimab | Orilanolimab in vivo | Orilanolimab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.